The survival motor neuron (SMN) protein is best known as the molecule whose shortage causes spinal muscular atrophy, one of the leading genetic causes of infant death. But reducing SMN to “the SMA protein” undersells it. SMN orchestrates the assembly of the molecular machinery cells need to process genetic instructions, shuttles cargo along nerve fibers, and even helps protect DNA from damage. Understanding what SMN does when it is abundant, and what goes wrong when it is scarce, explains both the devastating course of SMA and the logic behind the therapies now transforming outcomes for patients.
What SMN Actually Does Inside a Cell
SMN sits at the center of a large protein complex that includes partners known as Gemins 2 through 7. Together, this complex assembles Sm proteins onto small nuclear RNAs, forming the small nuclear ribonucleoproteins (snRNPs) that every cell needs to splice pre-messenger RNA into finished instructions for making proteins.1PubMed Central. Gemin proteins are required for efficient assembly of Sm-class ribonucleoproteins Without competent snRNP assembly, cells cannot accurately edit their genetic transcripts, and the downstream effects cascade through virtually every tissue.
A key structural feature of SMN is its Tudor domain, a region near the middle of the protein. The Tudor domain presents a negatively charged surface that recognizes and binds the arginine- and glycine-rich tails of Sm proteins, anchoring the interaction that makes snRNP assembly possible.2PubMed. SMN tudor domain structure and its interaction with the Sm proteins Disruptions to this domain, whether from mutations or reduced protein levels, compromise the entire assembly line.
Where SMN Lives Inside the Cell
SMN is not evenly scattered throughout the cell. In the nucleus, it concentrates in structures called Cajal bodies, which are small compartments involved in processing and maturing snRNPs. SMN reaches Cajal bodies through a direct interaction with coilin, the signature protein of these structures. A hallmark of cells from SMA patients is that SMN fails to accumulate properly in nuclear foci, and experiments have confirmed that the coilin interaction is what normally recruits SMN there.3PubMed Central. Coilin forms the bridge between Cajal bodies and SMN, the spinal muscular atrophy protein
SMN also forms its own distinct nuclear bodies called gems (short for “Gemini of Cajal bodies”). During neuronal differentiation, both the total amount of SMN and its recruitment to Cajal bodies increase, and additional gems appear as cells mature. In undifferentiated cells, Cajal bodies tend to lack SMN, but as cells take on a neuronal identity, SMN is progressively shuttled into these compartments.4PubMed Central. Targeting SMN to Cajal bodies and nuclear gems during neuritogenesis The fact that gem number tracks with neuronal maturation hints at why motor neurons are so sensitive to SMN loss.
The Special Relationship Between SMN and Motor Neurons
Every cell in the body uses SMN for snRNP assembly, yet motor neurons in the spinal cord are disproportionately devastated when SMN levels drop. Research over the past two decades has uncovered a second, neuron-specific job for SMN: managing messenger RNA transport along axons. Motor neurons are extraordinarily long cells, sometimes stretching a meter from the spinal cord to a distant muscle. Getting the right mRNA molecules to the right place at the right time is critical for maintaining the connections between nerve and muscle.
SMN has been found traveling in axonal transport granules and interacting with numerous mRNA-binding proteins that have nothing to do with splicing. This points to a role in assembling, stabilizing, or localizing axonal messenger ribonucleoprotein complexes.5PubMed Central. Spinal muscular atrophy: the role of SMN in axonal mRNA regulation Studies in developing rat spinal cord showed SMN protein associated with cytoskeletal elements in dendrites and axons, particularly during the postnatal period when these neurons are maturing rapidly.6PubMed. Subcellular localization and axonal transport of the survival motor neuron (SMN) protein in the developing rat spinal cord If SMN helps ferry specific mRNAs to distant axon terminals, its absence would leave motor neurons unable to maintain their synapses with muscle, explaining why neuromuscular junctions deteriorate early in SMA.
Why Not All Motor Neurons Are Equally Vulnerable
Even within the motor neuron population, some groups die early while others resist degeneration. Researchers studying SMA mouse models found that disease susceptibility correlates with a motor neuron’s baseline energy profile. Motor neurons innervating certain muscles (like those controlling the shin) are inherently vulnerable, while those serving other muscles (like those controlling finger extension) resist damage longer.7PubMed Central. Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy
Transcriptional profiling of vulnerable versus resistant motor neurons before symptoms even appear has revealed that low SMN drives down genes involved in ribosome function, energy production, and DNA repair. Activation of the cell-death pathway mediated by p53 precedes the loss of neuromuscular junctions, suggesting that internal cellular stress kills the neuron first, and the disconnection from muscle follows as a consequence rather than a cause.8PubMed Central. Transcriptional profiling of differentially vulnerable motor neurons at pre-symptomatic stage in the Smn (2b/-) mouse model of spinal muscular atrophy
SMN and DNA Integrity
Beyond splicing and axonal transport, SMN appears to play a role in protecting DNA from damage. When SMN is depleted, cells accumulate structures called R-loops, in which newly made RNA threads back into the DNA double helix instead of moving on. These R-loops stall the normal copying and reading of genes, creating breaks in the DNA strand. In severe SMA models, widespread intron retention and markers of DNA damage have been observed in neurons of the spinal cord and brain.9PubMed Central. SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damage
SMN-deficient cells also show increased damage specifically at ribosomal DNA, the genes encoding the RNA components of ribosomes. This leads to impaired ribosomal RNA production and reduced protein synthesis overall. Researchers have found that SMN interacts with RNA polymerase I, the enzyme that transcribes ribosomal DNA, and that motor neurons lacking SMN are specifically deficient in a protein called DDX21 that normally resolves R-loops in the nucleolus.10PubMed Central. SMN-deficient cells exhibit increased ribosomal DNA damage These findings suggest that genomic instability, driven by R-loop accumulation and faulty DNA repair, may contribute to motor neuron death independently of the splicing defect.11PubMed Central. R-loop Mediated DNA Damage and Impaired DNA Repair in Spinal Muscular Atrophy
How SMN Protein Levels Are Controlled
Cells regulate SMN not just by controlling how much mRNA they make, but by controlling how quickly the protein is broken down. Full-length SMN is tagged with ubiquitin, a small marker that flags proteins for destruction by the proteasome. The truncated version of SMN produced predominantly by the SMN2 gene (called SMNΔ7, missing the segment encoded by exon 7) has a half-life roughly half that of the full-length protein, in part because it cannot form the stable oligomeric complexes that shield full-length SMN from degradation.12PubMed Central. Regulation of SMN protein stability The shorter-lived isoform produced from a fetal-tissue-specific transcript (called a-SMN) is similarly cleared rapidly by the proteasome.13PubMed Central. Different Stability and Proteasome-Mediated Degradation Rate of SMN Protein Isoforms
Working in the opposite direction is the enzyme Usp9x, a deubiquitinase that strips ubiquitin tags off SMN and slows its destruction. When Usp9x is experimentally removed from cells, more SMN accumulates in its ubiquitinated form and total SMN levels fall. When Usp9x is overexpressed, ubiquitinated SMN decreases and protein levels rise.14Journal of Biological Chemistry. Usp9x Deubiquitinates and Stabilizes the Survival Motor Neuron Protein This tug-of-war between ubiquitination and deubiquitination is one reason researchers have explored proteasome inhibitors and other strategies to boost SMN levels in SMA patients, though these approaches remain experimental.
The Genetic Root of SMA
Humans carry two nearly identical genes for SMN, called SMN1 and SMN2, sitting in a duplicated region of chromosome 5. The proteins they encode are identical in amino acid sequence. The critical difference is a single silent nucleotide change in exon 7 of SMN2: a C-to-T transition that does not alter the amino acid at that position but disrupts a splicing signal, causing most SMN2 transcripts to skip exon 7 entirely.15PubMed. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy The resulting truncated protein is unstable and largely nonfunctional. SMN2 therefore produces only a small fraction of usable, full-length SMN protein.16PubMed Central. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2
SMA arises when both copies of SMN1 are deleted or mutated. Patients then depend entirely on their SMN2 copies for whatever full-length SMN they can produce. The number of SMN2 copies a person carries strongly influences disease severity: more copies mean more total full-length protein and, in general, milder disease. Patients with two SMN2 copies typically develop the most severe form (SMA type 1), while those with three or four copies often have later-onset, milder forms.
An Evolutionary Quirk Unique to Humans
The SMN gene duplication occurred more than five million years ago, before the human and chimpanzee lineages diverged. Chimpanzees carry multiple copies of the SMN gene per genome. However, the specific nucleotide changes in exons 7 and 8 that define SMN2 and cause it to skip exon 7 are absent in all non-human primates studied to date. SMN2 appears for the first time in Homo sapiens and has been detected in every human population examined worldwide.17PubMed Central. SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens This means SMA, as it exists clinically, is a uniquely human disease, a genetic vulnerability that emerged after our species diverged from other great apes.
SMA Beyond Motor Neurons
Because SMN is expressed in every cell, it should not be surprising that severe SMN deficiency affects organs beyond the nervous system. The heart has received the most attention. A systematic review identified structural cardiac problems, mainly septal defects and abnormalities of the cardiac outflow tract, predominantly in the most severely affected SMA type 1 patients. Cardiac rhythm disturbances, by contrast, were more frequently reported in patients with milder forms like SMA type 3.18PubMed Central. Cardiac pathology in spinal muscular atrophy: a systematic review
At the cellular level, heart muscle cells from a severe SMA mouse model show signs of impaired function even at early disease stages, with elevated heart-failure markers and slowed relaxation kinetics. Calcium handling is disrupted: the time it takes for SMN-deficient heart cells to clear calcium after a contraction is measurably longer than in healthy cells.19PubMed Central. SMN-deficiency disrupts SERCA2 expression and intracellular Ca2+ signaling in cardiomyocytes from SMA mice and patient-derived iPSCs These findings have practical implications for clinical care: monitoring heart function in SMA patients, especially those with the most severe forms, is becoming part of routine management.
Therapies That Target the SMN Pathway
The biology of SMN1 and SMN2 handed researchers a clear therapeutic target: if SMN2’s problem is that it skips exon 7, forcing it to include exon 7 should restore full-length protein production. Three approved therapies now exploit this logic, each through a different mechanism.
Nusinersen (brand name Spinraza) was the first approved treatment. It is an antisense oligonucleotide, a short synthetic strand of modified nucleic acid, injected directly into the spinal fluid. It binds to a specific silencing region in intron 7 of SMN2 pre-mRNA, blocking a repressor protein that would otherwise prevent exon 7 from being included in the mature transcript.20Frontiers in Cellular Neuroscience. History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy The result is increased production of full-length SMN protein from the patient’s existing SMN2 genes.21PubMed Central. Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes Because the drug does not cross the blood-brain barrier well on its own, it requires repeated lumbar punctures for administration.
Risdiplam (brand name Evrysdi) achieves a similar outcome through a different route. It is a small molecule taken by mouth that modifies SMN2 splicing systemically, meaning it reaches both the central nervous system and peripheral tissues. Its development established proof of concept for small-molecule splicing modifiers as a viable drug platform.22PubMed Central. Risdiplam, the First Approved Small Molecule Splicing Modifier Drug as a Blueprint for Future Transformative Medicines For families, the ability to take a liquid medicine at home rather than undergo spinal injections is a significant practical advantage.
The third approved therapy, onasemnogene abeparvovec (brand name Zolgensma), takes a fundamentally different approach. Instead of coaxing SMN2 to work harder, it delivers a functional copy of the SMN1 gene directly into cells using an adeno-associated virus (AAV9) vector. A single intravenous infusion can extend survival and help patients reach motor milestones they would otherwise never achieve. However, the approved dose is very high, and the drug carries a boxed warning for liver injury.23Molecular Therapy. Low-dose AAV9-SMN1 with CNS-selective expression delivers efficacy and favorable safety in spinal muscular atrophy
Next-Generation Gene Therapies in Development
Researchers are already working on improved viral vectors that address some of the limitations of the first-generation gene therapy. One approach uses a codon-optimized version of the SMN1 gene paired with the gene’s own natural promoter rather than the strong ubiquitous promoter used in the current product. In severe SMA mice, this second-generation vector restored SMN expression close to normal levels in both the central nervous system and major organs.24PubMed Central. Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor Long-term comparison studies in mice suggest that such vectors can improve survival and phenotypic outcomes compared with the current benchmark product.25Nature Communications. Long-term comparative analysis of AAV9-mediated gene replacement therapies for spinal muscular atrophy in mice
Another design under investigation uses a brain- and spinal-cord-selective regulatory cassette to drive SMN expression preferentially in the central nervous system, minimizing acute overexpression in the liver and other peripheral tissues. The goal is to achieve the same neurological benefit at a lower total dose, potentially reducing the toxicity that currently requires close monitoring after infusion.23Molecular Therapy. Low-dose AAV9-SMN1 with CNS-selective expression delivers efficacy and favorable safety in spinal muscular atrophy
Why Early Treatment Matters So Much
One of the clearest lessons from both animal studies and clinical trials is that timing is everything. In SMA type 1 patients, most motor neuron degeneration happens within the first months of life. Evidence from mice, large animals, and now human trials consistently shows that earlier intervention correlates with better motor function, longer survival, and sometimes near-normal development.26PubMed. Time Is Motor Neuron: Therapeutic Window and Its Correlation with Pathogenetic Mechanisms in Spinal Muscular Atrophy This is why newborn screening programs for SMA have expanded rapidly in recent years. Identifying affected infants before symptoms appear allows treatment to begin during the narrow window when the most motor neurons can still be rescued.
Biomarker research is also advancing to help clinicians track disease activity and treatment response. Neurofilament light chain, a protein released when nerve fibers are damaged, can be measured in a simple blood draw. In children with SMA, blood neurofilament levels correlate with motor function, particularly in the early stages of disease, making it a promising tool for monitoring how well therapy is working without waiting months for clinical milestones to change.27PubMed Central. Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children
SMN’s Connection to ALS
SMA is not the only motor neuron disease with ties to SMN. Amyotrophic lateral sclerosis (ALS), a degenerative disease that destroys motor neurons in adults, shares surprising biochemical overlap. The ALS-linked protein FUS physically associates with the SMN complex, and this interaction is partly mediated by snRNP components. Cells carrying severe ALS-causing FUS mutations lose their nuclear gems, the same SMN-containing structures that are depleted in SMA patient cells. The same gem loss has been observed in patient cells carrying mutations in TDP-43, another ALS-linked protein that interacts with FUS.28PubMed Central. FUS-SMN protein interactions link the motor neuron diseases ALS and SMA
Separately, mutant superoxide dismutase 1 (SOD1), the protein behind the most studied familial form of ALS, profoundly alters SMN’s subcellular localization, preventing it from forming gems by disrupting its recruitment to Cajal bodies.29Human Molecular Genetics. Mutant superoxide dismutase 1 (SOD1), a cause of amyotrophic lateral sclerosis, disrupts the recruitment of SMN, the spinal muscular atrophy protein to nuclear Cajal bodies These converging lines of evidence suggest that ALS and SMA, despite their very different genetics and clinical courses, share a biochemical pathway involving SMN and nuclear body formation. Whether modulating SMN levels could benefit ALS patients is an active area of inquiry, though no clinical application has emerged yet.
Practical Realities of Treatment Access
The approved SMA therapies rank among the most expensive drugs in the world. Onasemnogene abeparvovec was famously priced at over two million dollars for a single infusion at launch, while nusinersen requires ongoing spinal injections that carry a six-figure annual cost. Risdiplam, though less expensive per dose, still represents a significant long-term expenditure as a daily oral medication taken indefinitely. For families in countries without robust rare-disease coverage, access remains a serious barrier. Even in well-resourced health systems, insurance authorization delays can consume precious weeks during the therapeutic window described above. Newborn screening solves the diagnostic delay problem but creates a new one: identifying affected infants faster than treatment authorization and drug delivery systems can keep up.
These cost challenges are not unique to SMA. The broader trend of high-priced specialty biologics and gene therapies has prompted ongoing policy debates about value-based pricing, outcomes-based contracts, and international reference pricing. For SMA specifically, the existence of three mechanistically distinct approved therapies at least introduces some competitive pressure, and combination strategies using both a splicing modifier and gene therapy are being explored in clinical practice, though the economics of layering multiple expensive treatments remain daunting.